Telix Pharmaceuticals Limited (NASDAQ: TLX) Stock Competitors & Peer Comparison
See TLX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for TLX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TLX | $11.45 | +1.24% | 3.9B | 119.52 | $0.10 | N/A |
| VRTX | $526.19 | +0.73% | 133.5B | 27.65 | $19.03 | N/A |
| REGN | $788.04 | -1.00% | 81.2B | 17.27 | $45.63 | +0.47% |
| MRNA | $198.88 | +2.08% | 78.9B | -24.40 | -$8.15 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $959.49 | -0.28% | 59.7B | 34.60 | $27.73 | N/A |
| RVMDW | $11.63 | +8.09% | 44.7B | -1.29 | -$8.82 | N/A |
| RVMD | $204.97 | +2.56% | 43.6B | -23.24 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $360.85 | +0.24% | 38.6B | 63.53 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
TLX vs VRTX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, VRTX has a market cap of 133.5B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while VRTX trades at $526.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas VRTX's P/E ratio is 27.65. In terms of profitability, TLX's ROE is +0.07%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, TLX is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
TLX vs REGN Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, REGN has a market cap of 81.2B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while REGN trades at $788.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas REGN's P/E ratio is 17.27. In terms of profitability, TLX's ROE is +0.07%, compared to REGN's ROE of +0.14%. Regarding short-term risk, TLX is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for TLX.Check REGN's competition here
Moderna, Inc. (NASDAQ: MRNA)
TLX vs MRNA Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, MRNA has a market cap of 78.9B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while MRNA trades at $198.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas MRNA's P/E ratio is -24.40. In terms of profitability, TLX's ROE is +0.07%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, TLX is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for TLX.Check MRNA's competition here
Verona Pharma plc (NASDAQ: VRNA)
TLX vs VRNA Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas VRNA's P/E ratio is -102.80. In terms of profitability, TLX's ROE is +0.07%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, TLX is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for TLX.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
TLX vs ARGX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, ARGX has a market cap of 59.7B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while ARGX trades at $959.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas ARGX's P/E ratio is 34.60. In terms of profitability, TLX's ROE is +0.07%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, TLX is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check ARGX's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
TLX vs RVMDW Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, RVMDW has a market cap of 44.7B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while RVMDW trades at $11.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas RVMDW's P/E ratio is -1.29. In terms of profitability, TLX's ROE is +0.07%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, TLX is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for TLX.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
TLX vs RVMD Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, RVMD has a market cap of 43.6B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while RVMD trades at $204.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas RVMD's P/E ratio is -23.24. In terms of profitability, TLX's ROE is +0.07%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, TLX is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for TLX.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
TLX vs SGEN Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas SGEN's P/E ratio is -57.19. In terms of profitability, TLX's ROE is +0.07%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, TLX is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for TLX.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
TLX vs ONC Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, ONC has a market cap of 38.6B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while ONC trades at $360.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas ONC's P/E ratio is 63.53. In terms of profitability, TLX's ROE is +0.07%, compared to ONC's ROE of +0.14%. Regarding short-term risk, TLX is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
TLX vs ALNY Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, ALNY has a market cap of 34.2B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while ALNY trades at $255.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas ALNY's P/E ratio is 46.12. In terms of profitability, TLX's ROE is +0.07%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, TLX is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
TLX vs ROIV Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, ROIV has a market cap of 25.9B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while ROIV trades at $35.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas ROIV's P/E ratio is -34.06. In terms of profitability, TLX's ROE is +0.07%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, TLX is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
TLX vs INSM Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, INSM has a market cap of 25.5B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while INSM trades at $117.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas INSM's P/E ratio is -28.67. In terms of profitability, TLX's ROE is +0.07%, compared to INSM's ROE of -1.11%. Regarding short-term risk, TLX is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for TLX.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
TLX vs INCY Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, INCY has a market cap of 25.1B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while INCY trades at $123.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas INCY's P/E ratio is 16.65. In terms of profitability, TLX's ROE is +0.07%, compared to INCY's ROE of +0.30%. Regarding short-term risk, TLX is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for TLX.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
TLX vs BNTX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, BNTX has a market cap of 24.7B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while BNTX trades at $98.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas BNTX's P/E ratio is -12.78. In terms of profitability, TLX's ROE is +0.07%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, TLX is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check BNTX's competition here
Genmab A/S (NASDAQ: GMAB)
TLX vs GMAB Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, GMAB has a market cap of 21.7B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while GMAB trades at $35.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas GMAB's P/E ratio is 26.62. In terms of profitability, TLX's ROE is +0.07%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, TLX is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for TLX.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
TLX vs BGNE Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas BGNE's P/E ratio is -22.55. In terms of profitability, TLX's ROE is +0.07%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, TLX is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for TLX.Check BGNE's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
TLX vs UTHR Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, UTHR has a market cap of 20.2B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while UTHR trades at $475.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas UTHR's P/E ratio is 17.01. In terms of profitability, TLX's ROE is +0.07%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, TLX is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for TLX.Check UTHR's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
TLX vs DNA-WT Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, TLX's ROE is +0.07%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, TLX is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for TLX.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
TLX vs JAZZ Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, JAZZ has a market cap of 14.9B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while JAZZ trades at $237.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas JAZZ's P/E ratio is 8.87. In terms of profitability, TLX's ROE is +0.07%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, TLX is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for TLX.Check JAZZ's competition here
Exelixis, Inc. (NASDAQ: EXEL)
TLX vs EXEL Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, EXEL has a market cap of 14.6B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while EXEL trades at $58.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas EXEL's P/E ratio is 16.62. In terms of profitability, TLX's ROE is +0.07%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, TLX is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for TLX.Check EXEL's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
TLX vs ASND Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, ASND has a market cap of 14B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while ASND trades at $225.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas ASND's P/E ratio is -93.22. In terms of profitability, TLX's ROE is +0.07%, compared to ASND's ROE of +1.90%. Regarding short-term risk, TLX is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
TLX vs NBIX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, NBIX has a market cap of 13.9B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while NBIX trades at $138.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas NBIX's P/E ratio is 19.96. In terms of profitability, TLX's ROE is +0.07%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, TLX is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check NBIX's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
TLX vs HALO Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, HALO has a market cap of 13.5B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while HALO trades at $113.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas HALO's P/E ratio is 21.25. In terms of profitability, TLX's ROE is +0.07%, compared to HALO's ROE of +1.81%. Regarding short-term risk, TLX is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for TLX.Check HALO's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
TLX vs BBIO Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, BBIO has a market cap of 12.8B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while BBIO trades at $65.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas BBIO's P/E ratio is -17.53. In terms of profitability, TLX's ROE is +0.07%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, TLX is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for TLX.Check BBIO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
TLX vs KRTX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas KRTX's P/E ratio is -28.09. In terms of profitability, TLX's ROE is +0.07%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, TLX is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check KRTX's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
TLX vs SMMT Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, SMMT has a market cap of 12.5B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while SMMT trades at $15.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas SMMT's P/E ratio is -13.94. In terms of profitability, TLX's ROE is +0.07%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, TLX is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for TLX.Check SMMT's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
TLX vs MDGL Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, MDGL has a market cap of 11.9B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while MDGL trades at $516.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas MDGL's P/E ratio is -40.36. In terms of profitability, TLX's ROE is +0.07%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, TLX is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for TLX.Check MDGL's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
TLX vs BMRN Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while BMRN trades at $60.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas BMRN's P/E ratio is 28.97. In terms of profitability, TLX's ROE is +0.07%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, TLX is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for TLX.Check BMRN's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
TLX vs TWST Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, TWST has a market cap of 11.4B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while TWST trades at $182.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas TWST's P/E ratio is -82.44. In terms of profitability, TLX's ROE is +0.07%, compared to TWST's ROE of -0.30%. Regarding short-term risk, TLX is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for TLX.Check TWST's competition here
Bio-Techne Corporation (NASDAQ: TECH)
TLX vs TECH Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while TECH trades at $72.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas TECH's P/E ratio is 37.43. In terms of profitability, TLX's ROE is +0.07%, compared to TECH's ROE of +0.09%. Regarding short-term risk, TLX is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for TLX.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
TLX vs RNAM Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas RNAM's P/E ratio is -17.39. In terms of profitability, TLX's ROE is +0.07%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, TLX is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for TLX.Check RNAM's competition here
10x Genomics, Inc. (NASDAQ: TXG)
TLX vs TXG Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, TXG has a market cap of 10.9B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while TXG trades at $85.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas TXG's P/E ratio is -145.27. In terms of profitability, TLX's ROE is +0.07%, compared to TXG's ROE of -0.09%. Regarding short-term risk, TLX is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for TLX.Check TXG's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
TLX vs KRYS Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, KRYS has a market cap of 10.2B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while KRYS trades at $345.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas KRYS's P/E ratio is 43.34. In terms of profitability, TLX's ROE is +0.07%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, TLX is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for TLX.Check KRYS's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
TLX vs AXSM Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, AXSM has a market cap of 10B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while AXSM trades at $195.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas AXSM's P/E ratio is -50.94. In terms of profitability, TLX's ROE is +0.07%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, TLX is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for TLX.Check AXSM's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
TLX vs RXDX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas RXDX's P/E ratio is -56.47. In terms of profitability, TLX's ROE is +0.07%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, TLX is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check RXDX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
TLX vs ARWR Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, ARWR has a market cap of 9.3B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while ARWR trades at $65.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas ARWR's P/E ratio is -29.30. In terms of profitability, TLX's ROE is +0.07%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, TLX is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ARWR's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
TLX vs KYMR Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, KYMR has a market cap of 9.2B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while KYMR trades at $111.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas KYMR's P/E ratio is -34.98. In terms of profitability, TLX's ROE is +0.07%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, TLX is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for TLX.Check KYMR's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
TLX vs NUVL Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas NUVL's P/E ratio is -21.79. In terms of profitability, TLX's ROE is +0.07%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, TLX is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for TLX.Check NUVL's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
TLX vs PTGX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, PTGX has a market cap of 9.1B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while PTGX trades at $141.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas PTGX's P/E ratio is 137.73. In terms of profitability, TLX's ROE is +0.07%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, TLX is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check PTGX's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
TLX vs CAI Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, CAI has a market cap of 9B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while CAI trades at $31.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas CAI's P/E ratio is 89.86. In terms of profitability, TLX's ROE is +0.07%, compared to CAI's ROE of +0.19%. Regarding short-term risk, TLX is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for TLX.Check CAI's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
TLX vs CRNX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas CRNX's P/E ratio is -16.86. In terms of profitability, TLX's ROE is +0.07%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, TLX is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check CRNX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
TLX vs IBRX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, IBRX has a market cap of 8.8B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while IBRX trades at $8.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas IBRX's P/E ratio is -8.70. In terms of profitability, TLX's ROE is +0.07%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, TLX is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check IBRX's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
TLX vs TGTX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, TGTX has a market cap of 8.8B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while TGTX trades at $57.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas TGTX's P/E ratio is 20.81. In terms of profitability, TLX's ROE is +0.07%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, TLX is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check TGTX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
TLX vs IMGN Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas IMGN's P/E ratio is -111.55. In terms of profitability, TLX's ROE is +0.07%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, TLX is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for TLX.Check IMGN's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
TLX vs BPMC Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas BPMC's P/E ratio is -51.58. In terms of profitability, TLX's ROE is +0.07%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, TLX is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for TLX.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
TLX vs APGE Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas APGE's P/E ratio is -31.19. In terms of profitability, TLX's ROE is +0.07%, compared to APGE's ROE of -0.30%. Regarding short-term risk, TLX is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for TLX.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
TLX vs CERE Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas CERE's P/E ratio is -16.47. In terms of profitability, TLX's ROE is +0.07%, compared to CERE's ROE of -0.72%. Regarding short-term risk, TLX is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for TLX.Check CERE's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
TLX vs PCVX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, PCVX has a market cap of 8.1B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while PCVX trades at $56.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas PCVX's P/E ratio is -7.37. In terms of profitability, TLX's ROE is +0.07%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, TLX is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check PCVX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
TLX vs CYTK Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, CYTK has a market cap of 8B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while CYTK trades at $64.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas CYTK's P/E ratio is -8.96. In terms of profitability, TLX's ROE is +0.07%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, TLX is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for TLX.Check CYTK's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
TLX vs PRAX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, PRAX has a market cap of 7.8B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while PRAX trades at $280.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas PRAX's P/E ratio is -21.72. In terms of profitability, TLX's ROE is +0.07%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, TLX is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check PRAX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
TLX vs SYRE Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, SYRE has a market cap of 7.4B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while SYRE trades at $85.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas SYRE's P/E ratio is -43.94. In terms of profitability, TLX's ROE is +0.07%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, TLX is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for TLX.Check SYRE's competition here
Metsera, Inc. (NASDAQ: MTSR)
TLX vs MTSR Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas MTSR's P/E ratio is -23.58. In terms of profitability, TLX's ROE is +0.07%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, TLX is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for TLX.Check MTSR's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
TLX vs IONS Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, IONS has a market cap of 7.4B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while IONS trades at $44.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas IONS's P/E ratio is -13.61. In terms of profitability, TLX's ROE is +0.07%, compared to IONS's ROE of -1.11%. Regarding short-term risk, TLX is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for TLX.Check IONS's competition here
Immunovant, Inc. (NASDAQ: IMVT)
TLX vs IMVT Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, IMVT has a market cap of 6.9B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while IMVT trades at $33.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas IMVT's P/E ratio is -11.81. In terms of profitability, TLX's ROE is +0.07%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, TLX is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for TLX.Check IMVT's competition here
Merus N.V. (NASDAQ: MRUS)
TLX vs MRUS Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas MRUS's P/E ratio is -17.05. In terms of profitability, TLX's ROE is +0.07%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, TLX is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for TLX.Check MRUS's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
TLX vs RYTM Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while RYTM trades at $98.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas RYTM's P/E ratio is -31.72. In terms of profitability, TLX's ROE is +0.07%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, TLX is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for TLX.Check RYTM's competition here
Arcellx, Inc. (NASDAQ: ACLX)
TLX vs ACLX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas ACLX's P/E ratio is -28.27. In terms of profitability, TLX's ROE is +0.07%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, TLX is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check ACLX's competition here
Belite Bio, Inc (NASDAQ: BLTE)
TLX vs BLTE Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, BLTE has a market cap of 6.7B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while BLTE trades at $167.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas BLTE's P/E ratio is -89.48. In terms of profitability, TLX's ROE is +0.07%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, TLX is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for TLX.Check BLTE's competition here
Abivax S.A. (NASDAQ: ABVX)
TLX vs ABVX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, ABVX has a market cap of 6.7B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while ABVX trades at $91.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas ABVX's P/E ratio is -17.33. In terms of profitability, TLX's ROE is +0.07%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, TLX is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ABVX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
TLX vs RETA Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas RETA's P/E ratio is -66.29. In terms of profitability, TLX's ROE is +0.07%, compared to RETA's ROE of +0.47%. Regarding short-term risk, TLX is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for TLX.Check RETA's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
TLX vs CNTA Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas CNTA's P/E ratio is -22.63. In terms of profitability, TLX's ROE is +0.07%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, TLX is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for TLX.Check CNTA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
TLX vs LGND Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, LGND has a market cap of 6B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while LGND trades at $301.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas LGND's P/E ratio is 33.10. In terms of profitability, TLX's ROE is +0.07%, compared to LGND's ROE of +0.20%. Regarding short-term risk, TLX is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for TLX.Check LGND's competition here
CG Oncology Inc. (NASDAQ: CGON)
TLX vs CGON Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, CGON has a market cap of 5.9B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while CGON trades at $67.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas CGON's P/E ratio is -24.96. In terms of profitability, TLX's ROE is +0.07%, compared to CGON's ROE of -0.25%. Regarding short-term risk, TLX is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for TLX.Check CGON's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
TLX vs SRRK Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, SRRK has a market cap of 5.8B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while SRRK trades at $48.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas SRRK's P/E ratio is -14.10. In terms of profitability, TLX's ROE is +0.07%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, TLX is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for TLX.Check SRRK's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
TLX vs CDTX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas CDTX's P/E ratio is -19.77. In terms of profitability, TLX's ROE is +0.07%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, TLX is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check CDTX's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
TLX vs TVTX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, TVTX has a market cap of 5.5B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while TVTX trades at $59.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas TVTX's P/E ratio is -132.09. In terms of profitability, TLX's ROE is +0.07%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, TLX is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check TVTX's competition here
Abcam plc (NASDAQ: ABCM)
TLX vs ABCM Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, TLX's ROE is +0.07%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, TLX is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for TLX.Check ABCM's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
TLX vs COGT Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, COGT has a market cap of 5.5B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while COGT trades at $32.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas COGT's P/E ratio is -15.31. In terms of profitability, TLX's ROE is +0.07%, compared to COGT's ROE of -0.73%. Regarding short-term risk, TLX is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for TLX.Check COGT's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
TLX vs ISEE Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas ISEE's P/E ratio is -22.44. In terms of profitability, TLX's ROE is +0.07%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, TLX is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for TLX.Check ISEE's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
TLX vs MIRM Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, MIRM has a market cap of 5.5B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while MIRM trades at $89.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas MIRM's P/E ratio is -6.16. In terms of profitability, TLX's ROE is +0.07%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, TLX is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for TLX.Check MIRM's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
TLX vs APLS Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas APLS's P/E ratio is 38.35. In terms of profitability, TLX's ROE is +0.07%, compared to APLS's ROE of +0.40%. Regarding short-term risk, TLX is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for TLX.Check APLS's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
TLX vs PTCT Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, PTCT has a market cap of 5.2B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while PTCT trades at $62.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas PTCT's P/E ratio is -26.90. In terms of profitability, TLX's ROE is +0.07%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, TLX is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for TLX.Check PTCT's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
TLX vs CRSP Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while CRSP trades at $54.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas CRSP's P/E ratio is -11.39. In terms of profitability, TLX's ROE is +0.07%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, TLX is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for TLX.Check CRSP's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
TLX vs ORKA Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, ORKA has a market cap of 5.1B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while ORKA trades at $84.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas ORKA's P/E ratio is -43.54. In terms of profitability, TLX's ROE is +0.07%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, TLX is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ORKA's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
TLX vs DNTH Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, DNTH has a market cap of 5B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while DNTH trades at $88.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas DNTH's P/E ratio is -21.34. In terms of profitability, TLX's ROE is +0.07%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, TLX is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for TLX.Check DNTH's competition here
Erasca, Inc. (NASDAQ: ERAS)
TLX vs ERAS Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, ERAS has a market cap of 4.9B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while ERAS trades at $14.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas ERAS's P/E ratio is -15.32. In terms of profitability, TLX's ROE is +0.07%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, TLX is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ERAS's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
TLX vs IOVA Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, IOVA has a market cap of 4.9B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while IOVA trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas IOVA's P/E ratio is -15.07. In terms of profitability, TLX's ROE is +0.07%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, TLX is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for TLX.Check IOVA's competition here
Veradermics, Incorporated (NYSE: MANE)
TLX vs MANE Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, MANE has a market cap of 4.9B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while MANE trades at $116.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas MANE's P/E ratio is -37.15. In terms of profitability, TLX's ROE is +0.07%, compared to MANE's ROE of -0.38%. Regarding short-term risk, TLX is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for TLX.Check MANE's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
TLX vs DFTX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, DFTX has a market cap of 4.8B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while DFTX trades at $36.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas DFTX's P/E ratio is N/A. In terms of profitability, TLX's ROE is +0.07%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, TLX is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check DFTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
TLX vs TERN Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas TERN's P/E ratio is -51.41. In terms of profitability, TLX's ROE is +0.07%, compared to TERN's ROE of -0.20%. Regarding short-term risk, TLX is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for TLX.Check TERN's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
TLX vs ADPT Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, ADPT has a market cap of 4.7B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while ADPT trades at $29.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas ADPT's P/E ratio is -71.78. In terms of profitability, TLX's ROE is +0.07%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, TLX is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ADPT's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
TLX vs FOLD Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas FOLD's P/E ratio is -161.00. In terms of profitability, TLX's ROE is +0.07%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, TLX is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for TLX.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
TLX vs AKRO Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas AKRO's P/E ratio is -14.57. In terms of profitability, TLX's ROE is +0.07%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, TLX is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for TLX.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
TLX vs ALPN Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas ALPN's P/E ratio is -101.52. In terms of profitability, TLX's ROE is +0.07%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, TLX is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for TLX.Check ALPN's competition here
Opthea Limited (NASDAQ: OPT)
TLX vs OPT Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas OPT's P/E ratio is -1.52. In terms of profitability, TLX's ROE is +0.07%, compared to OPT's ROE of +1.18%. Regarding short-term risk, TLX is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for TLX.Check OPT's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
TLX vs EWTX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, EWTX has a market cap of 4.2B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while EWTX trades at $39.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas EWTX's P/E ratio is -21.26. In terms of profitability, TLX's ROE is +0.07%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, TLX is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check EWTX's competition here
PureTech Health plc (NASDAQ: PRTC)
TLX vs PRTC Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas PRTC's P/E ratio is -3.78. In terms of profitability, TLX's ROE is +0.07%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, TLX is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for TLX.Check PRTC's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
TLX vs VKTX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, VKTX has a market cap of 4.1B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while VKTX trades at $35.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas VKTX's P/E ratio is -7.63. In terms of profitability, TLX's ROE is +0.07%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, TLX is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check VKTX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
TLX vs MRTX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas MRTX's P/E ratio is -4.82. In terms of profitability, TLX's ROE is +0.07%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, TLX is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check MRTX's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
TLX vs TNGX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, TNGX has a market cap of 4.1B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while TNGX trades at $24.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas TNGX's P/E ratio is -30.02. In terms of profitability, TLX's ROE is +0.07%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, TLX is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for TLX.Check TNGX's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
TLX vs ABCL Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while ABCL trades at $12.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas ABCL's P/E ratio is -23.52. In terms of profitability, TLX's ROE is +0.07%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, TLX is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ABCL's competition here
Celcuity Inc. (NASDAQ: CELC)
TLX vs CELC Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, CELC has a market cap of 3.9B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while CELC trades at $79.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas CELC's P/E ratio is -18.49. In terms of profitability, TLX's ROE is +0.07%, compared to CELC's ROE of -3.51%. Regarding short-term risk, TLX is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for TLX.Check CELC's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
TLX vs CPRX Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas CPRX's P/E ratio is 17.49. In terms of profitability, TLX's ROE is +0.07%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, TLX is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for TLX.Check CPRX's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
TLX vs RLAY Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, RLAY has a market cap of 3.8B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while RLAY trades at $17.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas RLAY's P/E ratio is -11.13. In terms of profitability, TLX's ROE is +0.07%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, TLX is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for TLX.Check RLAY's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
TLX vs RYZB Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas RYZB's P/E ratio is -57.86. In terms of profitability, TLX's ROE is +0.07%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, TLX is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for TLX.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
TLX vs CBAY Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas CBAY's P/E ratio is -32.81. In terms of profitability, TLX's ROE is +0.07%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, TLX is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for TLX.Check CBAY's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
TLX vs PBLS Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, PBLS has a market cap of 3.6B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while PBLS trades at $31.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas PBLS's P/E ratio is -16.60. In terms of profitability, TLX's ROE is +0.07%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, TLX is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for TLX.Check PBLS's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
TLX vs XENE Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, XENE has a market cap of 3.6B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while XENE trades at $36.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas XENE's P/E ratio is -7.86. In terms of profitability, TLX's ROE is +0.07%, compared to XENE's ROE of -0.44%. Regarding short-term risk, TLX is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for TLX.Check XENE's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
TLX vs ACAD Comparison September 2026
Telix Pharmaceuticals Limited (NASDAQ: TLX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TLX stands at 3.9B. In comparison, ACAD has a market cap of 3.5B. Regarding current trading prices, TLX is priced at $11.45 on the NASDAQ, while ACAD trades at $20.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TLX currently has a P/E ratio of 119.52, whereas ACAD's P/E ratio is 9.32. In terms of profitability, TLX's ROE is +0.07%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, TLX is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for TLX.Check ACAD's competition here